New Alzheimer’s Drug Donanemab Slows Disease Progression by Up to 35%
Breaking news in the battle against Alzheimer’s: a new drug called Donanemab is being hailed as a game-changer. Clinical trials show it can slow the disease’s progression by up to 35%, helping sufferers hold onto everyday tasks like shopping, managing money, and taking medication.
Medical Experts See a New Era for Alzheimer’s Treatment
The drug’s success has sparked huge optimism. Alzheimer’s Research UK claimed, “We’re entering a new era where Alzheimer’s disease could become treatable.” The Alzheimer’s Society added that treatments like Donanemab could turn Alzheimer’s into a manageable condition, similar to asthma.
How Donanemab Works
Donanemab targets and clears amyloid plaques — sticky proteins building up in the brains of Alzheimer’s patients. The impressive results come from the TRAILBLAZER ALZ-2 trial. Nearly 1,800 participants in early Alzheimer’s stages received either monthly Donanemab infusions or placebos over 18 months.
Key Findings from the Trial
- Donanemab slowed clinical decline by 35.1% in patients with low to medium tau protein levels, as shown in brain scans.
- A 22.3% slowdown was seen across patients with various tau protein levels.
- Those in earlier disease stages and with lower brain amyloid levels saw greater benefits.
- Patients retained more abilities like chatting, taking calls, and enjoying hobbies.
- Overall disease progression slowed by 20-30%, with some patients experiencing up to 40% improvement.
- Half the patients cleared enough brain deposits after a year to stop the treatment.
- Side effects were noted, so patients must be aware of potential risks.
While more research is needed to confirm long-term safety, Donanemab offers a beacon of hope to millions battling Alzheimer’s. This could mark a landmark breakthrough in tackling this devastating disease.
